Abstract
Purpose :
Ocular manifestations of GVHD are known to occur in 60–90% of patients with chronic GVHD, and these manifestations primarily
affect the cornea, conjunctiva, lacrimal glands, eyelid and meibomian glands. Dry eye disease (DED), or keratoconjunctivitis
sicca (KCS), is the most common manifestation of ocular GVHD. We evaluated the changes of an ocular surface and meibomian glandsafter HSCT associated with related with symptoms for the dry eye.
Methods :
This retrospective, noncomparative, observational study was approved by the Seoul St Mary’s Hospital Institutional Review Board.This study included the patients who had systemic or ocular inflammatory diseases or retinal diseases were excluded. The enrolled patients were checked up on visual acuity, intra ocular pressure (IOP), slit lamp examinationss to confirm the corneal surface and the tear function, and meibography before and after HSCT; one, two, and 3 months, respectively. Simultaneously, the degree of subjective symptoms about dry eye was also investigated.
Results :
Total 96 eyes of 48 patients were included. As compared with the group (before HSCT), there is statistical significance of aggravated tear break-up time (p < 0.05), Schirmer test score (p < 0.05), OSDI score (p < 0.05), ocular staining score (Oxford) (p < 0.05), meibography score (p<0.05) in other groups (1, 2, and 3 months after HSCT, respectively). Twenty one patients (55.26%) showed newly developed drop out lesion of meibimina gland duct during the follow-up period.
Conclusions :
HSCT aggravated the instability of ocular surface and meibomian glands. These changes might cause subjective ocular discomforts in patients after HSCT.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.